Antitumor activity of NF-κB decoy oligodeoxynucleotides in a prostate cancer cell line

Asian Pacific Journal of Cancer Prevention

Volumn 12, Issue 10, 2011, Pages 2721-2726

  Fang, Yongqi ^a   Sun, Hongli ^a   Zhai, Jing ^a   Zhang, Yuanying ^a   Yi, Shuying ^a   Hao, Gangping ^a   Wang, Tao ^a  

^a TAISHAN MEDICAL UNIVERSITY   (China)

Author keywords

Apoptosis; Decoy oligodeoxynucleotides; NF B; Prostate cancer

Indexed keywords

EID: 84863295223     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Hsing AW, Tsao L, Devesa SS (2000): International trends and patterns of prostate cancer incidence and mortality. Int J Cancer, 85, 60-7.
2. Jemal A, Murray T, Samuels A, et al (2003). Cancer statistics. CA Cancer J Clin, 53, 5-26.
3. Morton RA, Isaacs WB (1998): Molecular genetics of prostate cancer: clinical applications. J Natl Med Assoc, 90, 5728-31.
4. Karin M, Lin A (2002). NF-κB at the crossroads of life and death. Nat Immunol, 3, 221-7.
5. Kumar A, TakadaY, Boriek AM, Aggarwal BB (2004). Nuclear factor-kappaB: Its role in health and disease. J MolMed, 82, 434-48.
6. Rius J, Guma M, Schachtrup C, et al (2008). NF-κB links innate immunity to the hypoxic response through transcriptional regulation of HIF-1 alpha. Nature, 453, 807-11
7. Oliver KM, Taylor CT, Cummins EP (2009). Hypoxia regulation of NF-kappaB signalling during inflammation: The role of hydroxylases. ArthritisResTher, 11, 215.
8. Walmsley SR, Print C, Farahi N, et al (2005). Hypoxia-induced neutrophil survival ismediated by HIF-1 alpha-dependent NF-κB activity. J Exp Med, 201, 105-15.
9. Maxwell PJ, Gallagher R, Seaton A, W ilson C, Scullin P, Pettigrew J, et al (2007). HIF-1 and NF-κB-mediated upregulation ofCXCR1 and CXCR2 expression promotes cell survival in hypoxic prostate cancer cells [J]. Oncogene, 26, 7333-45.
10. Bollrath J, Greten FR. IKK/NF-κB and STAT3 pathways (2009): Central signalling hubs in inflammation-mediated tumour promotion and metastasis. EMBO, 10, 1314-9.
11. LeeH, Herrmann A, Deng JH, et al (2009). Persistently activated Stat3 maintains constitutiveNF-κB activity in tumors. Cancer Cell, 15, 283-93.
12. Domingo-Domenech J, Oliva C, Rovira A, et al (2006). Interleukin 6, a nuclear factor-kappaB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-kappaB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res, 12, 5578-86
13. Benitez DA, Hermoso MA, Pozo-Guisado E, et al (2009). Regulation of cell survival by resveratrol involves inhibition of NF-kappaB-regulated gene expression in prostate cancer cells. Prostate, 69, 1045-54.
14. Domingo-Domenech J, Mellado B, Ferrer B, et al (2005). Activation of nuclear factor-kappaB in human prostate carcinogenesis and association to biochemical relapse. Br J Cancer, 93, 1285-94.
15. Doi TS, Marino MW, Takahashi T, et al (1999). Absence of tumor necrosis factor rescues RelA-deficient mice from embryonic lethality. Proc Natl Acad Sci USA, 96, 2994-9.
16. Sen R, Baltimore D (1986). Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 46, 705-6.
17. Shah N, Thomas TJ, Lewis JS, et al (2001). Regulation of estrogenic and nuclear factor kappa B functions by polyamines and their role in polyamine analog-induced apoptosis of breast cancer cells. Ocongene, 20, 1715-29
18. Baldwin AS Jr (1996). The NF-kappa B and I kappa B proteins: new discoveries and insights. Annu Rev Immunol, 14, 649-83.
19. Beg AA, Baltimore D (1996). An essential role for NF-kappaB in preventing TNF-alpha-induced cell death. Science, 274, 782-4.
20. Perkins ND (2000). The Rel/NF-kappa B family: friend and foe. Trends Biochem Sci, 25, 434-40.
21. Tomita N, Kashihara N, Morishita R, et al (2007). Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease. Clin Exp Nephrol, 11, 7-17.
22. Edwards MR, Bartlett NW, Clarke D, et al (2009). Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther, 121, 1-13.
23. Shimizu H, Nakagami H, Tsukamoto I, et al (2006). NF-kappaB decoy oligodeoxynucleotides ameliorates osteoporosis through inhibition of activation and differentiation of osteoclasts. Gene Ther, 13, 933-41.
24. Yamasaki K, Asai T, Shimizu M, et al (2003). Inhibition of NFkappaB activation using cis-element 'decoy' of NF kappaB binding site reduces neointimal formation in porcine balloon-injured coronary artery model. Gene Ther, 10, 356-64.